"Benzocycloheptenes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds consisting of the cycloheptene ring with one or two BENZENE rings fused to it.
| Descriptor ID |
D001567
|
| MeSH Number(s) |
D02.455.426.559.847.181 D04.615.181
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzocycloheptenes".
Below are MeSH descriptors whose meaning is more specific than "Benzocycloheptenes".
This graph shows the total number of publications written about "Benzocycloheptenes" by people in this website by year, and whether "Benzocycloheptenes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Benzocycloheptenes" by people in Profiles.
-
Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC. Cancer Res. 2021 03 01; 81(5):1398-1412.
-
The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. EMBO Rep. 2018 08; 19(8).
-
Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer. Cancer Res. 2018 01 01; 78(1):246-255.
-
Heterogeneity of pancreatic cancer metastases in a single patient revealed by quantitative proteomics. Mol Cell Proteomics. 2014 Nov; 13(11):2803-11.
-
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov. 2014 Jul; 4(7):816-27.
-
Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration. PLoS One. 2014; 9(2):e83957.
-
Synthesis of structurally diverse benzosuberene analogues and their biological evaluation as anti-cancer agents. Bioorg Med Chem. 2013 Dec 15; 21(24):8019-32.
-
The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Cancer Biol Ther. 2010 Nov 15; 10(10):1009-18.